UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029597
Receipt number R000033817
Scientific Title Revascularization by Peripheral Blood Mononuclear Cell Transplantation
Date of disclosure of the study information 2017/10/17
Last modified on 2021/09/13 09:08:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Revascularization by Peripheral Blood Mononuclear Cell Transplantation

Acronym

Revascularization by Peripheral Blood Mononuclear Cell Transplantation

Scientific Title

Revascularization by Peripheral Blood Mononuclear Cell Transplantation

Scientific Title:Acronym

Revascularization by Peripheral Blood Mononuclear Cell Transplantation

Region

Japan


Condition

Condition

Critical limb ischemia due to peripheral artery disease (critical limb ischemia) and Buerger's disease

Classification by specialty

Medicine in general Cardiology Dermatology
Plastic surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aims of this study is to demonstrate the benefit of peripheral blood mononuclear cell transplantation on critical limb ischemia.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Improvement of skin perfusion pressure at 6 weeks after initial administration of peripheral blood mononuclear cell transplantation.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

The concentrated solution of the patien ts' mononuclear cells administered to th e affected limb with ulcer lesions by int ramuscular injection. Repeat again the same treatment after two weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients with critical limb ischemia caused by peripheral artery disease or Burger's disease.
2) over 20 years old
3) patient who can take a informed con sent

Key exclusion criteria

1) Patients who have severe hypersensitivity or history of side effects to aphaeresis.
2) Patients who have malignant tumor or history of malignancy within the past 3 years.
3) Patients who have experienced acute myocardial infarction, unstable angina pectoris, myocarditis or cerebral infarction within 3 months.
4) Patients with active infection.
5) Patients who are pregnant or might be pregnant.
6) Patients with proliferative diabetic retinopathy (untreated, medium-term and late proliferative retinopathy)
the end of treatment example is excluded.
7) Patients with platelets less than 70,000 platelets in blood test just before apheresies.
8) Patients with less than serum albumin 2 mg/dL.
9) Patients who are judged inappropriate for this trial by their attending physician.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Kenichi
Middle name
Last name Tsujita

Organization

Graduate School of Medical Sciences, Kumamoto University

Division name

Department of Cardiovascular Medicine

Zip code

860-8556

Address

1-1-1 Honjo, Chuo-ku, Kumamoto, Japan

TEL

81-96-373-5175

Email

tsujita@kumamoto-u.ac.jp


Public contact

Name of contact person

1st name Koichiro
Middle name
Last name Fujisue

Organization

Kumamoto University Hospital

Division name

Department of Cardiovascular Medicine

Zip code

860-8556

Address

1-1-1 Honjo, Chuo-ku, Kumamoto, Japan.

TEL

81-96-373-5175

Homepage URL


Email

fujisues@kumamoto-u.ac.jp


Sponsor or person

Institute

Kumamoto University

Institute

Department

Personal name



Funding Source

Organization

Kumamoto University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

the Institutional Review Board or Independent Ethics Committee of Kumamoto University Graduate of Medicine

Address

1-1-1 Honjo, Chuo-ku, Kumamoto, Japan.

Tel

81-96-373-5657

Email

byi-senshin@jimu.kumamoto-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 10 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

6

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2017 Year 07 Month 10 Day

Date of IRB

2017 Year 07 Month 10 Day

Anticipated trial start date

2017 Year 10 Month 20 Day

Last follow-up date

2021 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 10 Month 17 Day

Last modified on

2021 Year 09 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033817


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name